The document discusses memantine, a drug approved by the FDA to treat symptoms of Alzheimer's disease. Researchers reviewed studies on memantine's effectiveness in patients with mild Alzheimer's. They found that memantine was no more effective than a placebo at treating the disease. The document also provides information on the progressive stages of Alzheimer's disease and generic drug brands approved to treat symptoms.
The document discusses current FDA-approved drugs for treating Alzheimer's disease symptoms like memantine (Namenda), as well as potential new treatments like CUBX, a hybrid drug that could act on both extracellular amyloid plaques and intracellular neurofibrillary tangles. It also mentions the large and growing societal costs of Alzheimer's care and the need to identify preventative strategies with no current cure available.
O documento classifica as plantas em dois grandes grupos, Criptógamas e Fanerógamas, que englobam quatro subclasses: Briófitas, Pteridófitas, Gimnospermas e Angiospermas. Cada subclasse possui características como presença ou ausência de vasos, sementes, flores e frutos.
El documento describe las características generales del reino plantas. Algunas de sus características incluyen tener una organización cormofítica, tener celulosa como su componente fundamental de la pared celular, almacenar almidón como sustancia de reserva y tener nutrición autótrofa. El reino plantas se divide en briofitas, pteridofitas, gimnospermas y angiospermas.
effectiveness of guava in lowering blood sugar of white miceManong Inday
This document presents a research proposal on studying the effectiveness of guava (Psidium guajava L.) leaves in lowering the blood sugar levels of white mice. It provides background on diabetes and different types. The study aims to determine the amount of guava leaf extract needed to lower blood sugar in mice after 2 weeks and the decrease in blood sugar levels. It reviews related studies showing guava leaves have antioxidant and liver protective properties. The conceptual framework discusses guava leaves' traditional medicinal use and potential benefits like lowering blood sugar. The significance is that it could provide an affordable treatment for diabetes.
The document discusses Alzheimer's disease (AD) and herbal treatments for it. It provides details on what AD is, risk factors, symptoms, and the plaques and tangles involved. Several herbal drugs that may help treat AD are then described in detail, including their active constituents, mechanisms of action, dosages, and other pharmacological properties. Key herbal drugs discussed are Ginkgo biloba, Galanthus woronowii, Curcuma longa, Centella asiatica, and others. The conclusion states that herbal treatments can help manage but not cure AD, and lifestyle changes along with herbal drugs are needed.
The rapid cure using Transfer Factor Science.
Team 4Life is a group of world-renowned athletes who excel in their disciplines and endorse 4Life Transfer Factor® products.
Global Team 4Life athletes include World Series starting pitcher Orlando Hernández (“El Duque”), Denver Broncos Offensive Guard Manuel "Manny" Ramirez, Super Bowl Champion Sam Madison, 2010 Baseball World Series Most Valuable Player (MVP) Edgar Rentería, World Golf Hall of Famer Johnny Miller, Ian Baker-Finch, winner on all-four major tours, world-class powerlifter Brady Stewart, Kona Ironman Triathlete Glenn Dobson, Karate World Champion Yohana Sánchez, Freestyle Aerialist Alexa Devereaux, and professional golfers Paosingh Nissaisook and Thitipong Na Songkhla in the Eastern Hemisphere and triathletes Ty Hopkins and Modesto Duran Riquelme in the Western Hemisphere.
Current management of alzheimer’s disease and amyloid peptidesDr Amit Mittal
Dr. Amit Mittal's document provides an overview of the current management of Alzheimer's disease and amyloid peptides. It discusses the pathology and clinical presentation of Alzheimer's, including memory loss and cognitive decline. Epidemiology statistics on the prevalence and worldwide burden of Alzheimer's are presented. The document reviews genetics, pathophysiology based on amyloid and tau proteins, diagnosis, and clinical assessment scales. Current drug treatments target cholinergic systems and NMDA receptors. Recent research focuses on preventing amyloid plaque and tau tangle formation through various mechanisms.
The document discusses current FDA-approved drugs for treating Alzheimer's disease symptoms like memantine (Namenda), as well as potential new treatments like CUBX, a hybrid drug that could act on both extracellular amyloid plaques and intracellular neurofibrillary tangles. It also mentions the large and growing societal costs of Alzheimer's care and the need to identify preventative strategies with no current cure available.
O documento classifica as plantas em dois grandes grupos, Criptógamas e Fanerógamas, que englobam quatro subclasses: Briófitas, Pteridófitas, Gimnospermas e Angiospermas. Cada subclasse possui características como presença ou ausência de vasos, sementes, flores e frutos.
El documento describe las características generales del reino plantas. Algunas de sus características incluyen tener una organización cormofítica, tener celulosa como su componente fundamental de la pared celular, almacenar almidón como sustancia de reserva y tener nutrición autótrofa. El reino plantas se divide en briofitas, pteridofitas, gimnospermas y angiospermas.
effectiveness of guava in lowering blood sugar of white miceManong Inday
This document presents a research proposal on studying the effectiveness of guava (Psidium guajava L.) leaves in lowering the blood sugar levels of white mice. It provides background on diabetes and different types. The study aims to determine the amount of guava leaf extract needed to lower blood sugar in mice after 2 weeks and the decrease in blood sugar levels. It reviews related studies showing guava leaves have antioxidant and liver protective properties. The conceptual framework discusses guava leaves' traditional medicinal use and potential benefits like lowering blood sugar. The significance is that it could provide an affordable treatment for diabetes.
The document discusses Alzheimer's disease (AD) and herbal treatments for it. It provides details on what AD is, risk factors, symptoms, and the plaques and tangles involved. Several herbal drugs that may help treat AD are then described in detail, including their active constituents, mechanisms of action, dosages, and other pharmacological properties. Key herbal drugs discussed are Ginkgo biloba, Galanthus woronowii, Curcuma longa, Centella asiatica, and others. The conclusion states that herbal treatments can help manage but not cure AD, and lifestyle changes along with herbal drugs are needed.
The rapid cure using Transfer Factor Science.
Team 4Life is a group of world-renowned athletes who excel in their disciplines and endorse 4Life Transfer Factor® products.
Global Team 4Life athletes include World Series starting pitcher Orlando Hernández (“El Duque”), Denver Broncos Offensive Guard Manuel "Manny" Ramirez, Super Bowl Champion Sam Madison, 2010 Baseball World Series Most Valuable Player (MVP) Edgar Rentería, World Golf Hall of Famer Johnny Miller, Ian Baker-Finch, winner on all-four major tours, world-class powerlifter Brady Stewart, Kona Ironman Triathlete Glenn Dobson, Karate World Champion Yohana Sánchez, Freestyle Aerialist Alexa Devereaux, and professional golfers Paosingh Nissaisook and Thitipong Na Songkhla in the Eastern Hemisphere and triathletes Ty Hopkins and Modesto Duran Riquelme in the Western Hemisphere.
Current management of alzheimer’s disease and amyloid peptidesDr Amit Mittal
Dr. Amit Mittal's document provides an overview of the current management of Alzheimer's disease and amyloid peptides. It discusses the pathology and clinical presentation of Alzheimer's, including memory loss and cognitive decline. Epidemiology statistics on the prevalence and worldwide burden of Alzheimer's are presented. The document reviews genetics, pathophysiology based on amyloid and tau proteins, diagnosis, and clinical assessment scales. Current drug treatments target cholinergic systems and NMDA receptors. Recent research focuses on preventing amyloid plaque and tau tangle formation through various mechanisms.
Here's breaking news for those affected by Alzheimer's! Four new drugs are being tested that work in a unique manner, unlike other current medicines. Below are the exciting details on these up-and-coming drugs.
http://www.homecareassistancephoenix.com/alzheimers-home-care/
Alzheimers disease medications
Several prescription drugs are currently approved by the U.S. Food and Drug Administration
(FDA) to treat people who have been diagnosed with Alzheimer’s disease. Treating the symptoms of Alzheimer’s can provide patients with comfort, dignity, and independence for a longer period of time and can encourage and assist their caregivers as well. It is important to understand that none of these medications stops the disease itself.
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
The document discusses Alzheimer's disease and treatments. It defines Alzheimer's as a progressive brain disease that destroys memory and cognitive functions. Symptoms include memory loss, mood changes, and problems completing tasks. Diagnosis involves tests like PET scans, cognitive assessments, and neurological exams. The disease is characterized by beta-amyloid plaques and neurofibrillary tangles in the brain. Current treatments aim to improve symptoms and slow progression by inhibiting acetylcholinesterase or blocking NMDA receptors, such as donepezil, rivastigmine, memantine, and galantamine.
This study evaluated the efficacy and safety of lacosamide in treating diabetic neuropathic pain through an 18-week double-blind trial of 370 patients with doses of 200 mg/day, 400 mg/day, and 600 mg/day compared to a placebo. The 400 mg/day dose was found to significantly improve pain scores over the placebo and had the optimal balance of efficacy and side effects. Common side effects included dizziness, tremor and headache. While lacosamide showed potential for treating diabetic neuropathic pain, the study period was short and the 600 mg/day group had a high withdrawal rate due to adverse events.
The document discusses several topics related to health and wellness. It provides information on skin anatomy and functions, processed foods consumption in the US, a study linking diet soda to obesity risk, risks of NSAIDs and congestive heart failure, how genes can be epigenetically influenced, quotes on the consequences of our actions, common symptoms associated with toxicity, diseases linked to toxicity, emotions and pH balance, sunscreen ingredients to avoid, leading causes of death in the US, and potential impacts of a super flu pandemic.
This document summarizes an interview between Mike Adams and Dr. Russell Blaylock about excitotoxins such as MSG and aspartame. Dr. Blaylock discusses how excitotoxins like MSG promote cancer growth and metastasis by making cancer cells more mobile. Research shows that glutamate blockers can enhance the effectiveness of chemotherapy in treating cancer. A recent Italian study found a link between aspartame consumption and increased rates of leukemia and lymphoma in animals. Industry suppression of this health information and the alliance between big business and the scientific community have allowed these chemicals to remain in the food supply.
Aduhelm, an Accelerated Approval for Alzheimer’sEMMAIntl
Alzheimer’s disease is the most common cause of dementia, especially in patients aged 65 and older1. Alzheimer’s disease is a neurodegenerative disease that has a direct correlation to age: as age increases, the likelihood of developing Alzheimer’s increases as well. Alzheimer’s has long been a subject of discussion in the pharmaceutical industries and, until the FDA’s recent accelerated approval of Aduhelm earlier this month, the most recent treatment approved for Alzheimer’s was in 2003, almost two decades ago. The FDA’s approval of Aduhelm represents the first-of-its-kind treatment and is the first therapy that aims to interrupt the underlying physiological pathway of Alzheimer’s, rather than simply attempt to treat its symptoms...
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara VishaIJARIIT
21st century is the world full of synthetics and everyone are living in the influence of synthetic substances. Altered life
styles, food habits and irregular sleep pattern had resulted not only Non communicable disease but also resulting in reduced
immunity and is risking the person more for infections. Pharma Industry has grown as big as hierarchy in recent centauries
and introduces new chemical molecules quoting as capable for treating diabetes, hypertension etc. But bitter truth is prolonged
usage these medications itself has adverse effect on liver and kidneys causes hepatotoxicity and nephrotoxicity or organs
specific toxicity.
This document provides an overview of epilepsy, including its epidemiology, classification, pathophysiology, signs and symptoms, and management. Epilepsy is a brain disorder caused by abnormal neuronal signaling that can cause changes in movement, behavior, or consciousness. Approximately 1% of the global population has epilepsy, with 80% of cases occurring in developing countries. While the specific cause is unknown in many cases, potential causes include brain trauma, lesions, infections, genetic factors, or substance abuse. Management involves use of anti-seizure medications like carbamazepine, phenytoin, and valproic acid. Surgery may also be an option for some patients to achieve total seizure control.
This document discusses pharmacogenomics, which is the study of how an individual's genetic makeup affects their response to drugs. It explains that people can metabolize and respond to drugs differently due to genetic variations. The goal of pharmacogenomics is to optimize drug therapy for each individual by selecting the right drug, dose, and time based on their genotype to maximize effectiveness and minimize side effects. It outlines how variations can influence whether receptors are present to bind drugs, other physiological traits, and how the body processes drugs through absorption, distribution, metabolism and excretion.
New treatment trends in alzheimer diseaseSarath Menon
This document summarizes new treatment trends in Alzheimer's disease. It discusses current treatments for mild-moderate Alzheimer's like donepezil, rivastigmine, and galantamine which are cholinesterase inhibitors. Memantine is used for more severe Alzheimer's as an NMDA receptor antagonist. Experimental therapies discussed include vaccines, secretase inhibitors, and stem cell therapy. Lifestyle factors like diet, exercise, and social support are also reviewed for prevention and management of Alzheimer's symptoms.
Here's breaking news for those affected by Alzheimer's! Four new drugs are being tested that work in a unique manner, unlike other current medicines. Below are the exciting details on these up-and-coming drugs.
http://www.homecareassistancephoenix.com/alzheimers-home-care/
Alzheimers disease medications
Several prescription drugs are currently approved by the U.S. Food and Drug Administration
(FDA) to treat people who have been diagnosed with Alzheimer’s disease. Treating the symptoms of Alzheimer’s can provide patients with comfort, dignity, and independence for a longer period of time and can encourage and assist their caregivers as well. It is important to understand that none of these medications stops the disease itself.
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
The document discusses Alzheimer's disease and treatments. It defines Alzheimer's as a progressive brain disease that destroys memory and cognitive functions. Symptoms include memory loss, mood changes, and problems completing tasks. Diagnosis involves tests like PET scans, cognitive assessments, and neurological exams. The disease is characterized by beta-amyloid plaques and neurofibrillary tangles in the brain. Current treatments aim to improve symptoms and slow progression by inhibiting acetylcholinesterase or blocking NMDA receptors, such as donepezil, rivastigmine, memantine, and galantamine.
This study evaluated the efficacy and safety of lacosamide in treating diabetic neuropathic pain through an 18-week double-blind trial of 370 patients with doses of 200 mg/day, 400 mg/day, and 600 mg/day compared to a placebo. The 400 mg/day dose was found to significantly improve pain scores over the placebo and had the optimal balance of efficacy and side effects. Common side effects included dizziness, tremor and headache. While lacosamide showed potential for treating diabetic neuropathic pain, the study period was short and the 600 mg/day group had a high withdrawal rate due to adverse events.
The document discusses several topics related to health and wellness. It provides information on skin anatomy and functions, processed foods consumption in the US, a study linking diet soda to obesity risk, risks of NSAIDs and congestive heart failure, how genes can be epigenetically influenced, quotes on the consequences of our actions, common symptoms associated with toxicity, diseases linked to toxicity, emotions and pH balance, sunscreen ingredients to avoid, leading causes of death in the US, and potential impacts of a super flu pandemic.
This document summarizes an interview between Mike Adams and Dr. Russell Blaylock about excitotoxins such as MSG and aspartame. Dr. Blaylock discusses how excitotoxins like MSG promote cancer growth and metastasis by making cancer cells more mobile. Research shows that glutamate blockers can enhance the effectiveness of chemotherapy in treating cancer. A recent Italian study found a link between aspartame consumption and increased rates of leukemia and lymphoma in animals. Industry suppression of this health information and the alliance between big business and the scientific community have allowed these chemicals to remain in the food supply.
Aduhelm, an Accelerated Approval for Alzheimer’sEMMAIntl
Alzheimer’s disease is the most common cause of dementia, especially in patients aged 65 and older1. Alzheimer’s disease is a neurodegenerative disease that has a direct correlation to age: as age increases, the likelihood of developing Alzheimer’s increases as well. Alzheimer’s has long been a subject of discussion in the pharmaceutical industries and, until the FDA’s recent accelerated approval of Aduhelm earlier this month, the most recent treatment approved for Alzheimer’s was in 2003, almost two decades ago. The FDA’s approval of Aduhelm represents the first-of-its-kind treatment and is the first therapy that aims to interrupt the underlying physiological pathway of Alzheimer’s, rather than simply attempt to treat its symptoms...
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara VishaIJARIIT
21st century is the world full of synthetics and everyone are living in the influence of synthetic substances. Altered life
styles, food habits and irregular sleep pattern had resulted not only Non communicable disease but also resulting in reduced
immunity and is risking the person more for infections. Pharma Industry has grown as big as hierarchy in recent centauries
and introduces new chemical molecules quoting as capable for treating diabetes, hypertension etc. But bitter truth is prolonged
usage these medications itself has adverse effect on liver and kidneys causes hepatotoxicity and nephrotoxicity or organs
specific toxicity.
This document provides an overview of epilepsy, including its epidemiology, classification, pathophysiology, signs and symptoms, and management. Epilepsy is a brain disorder caused by abnormal neuronal signaling that can cause changes in movement, behavior, or consciousness. Approximately 1% of the global population has epilepsy, with 80% of cases occurring in developing countries. While the specific cause is unknown in many cases, potential causes include brain trauma, lesions, infections, genetic factors, or substance abuse. Management involves use of anti-seizure medications like carbamazepine, phenytoin, and valproic acid. Surgery may also be an option for some patients to achieve total seizure control.
This document discusses pharmacogenomics, which is the study of how an individual's genetic makeup affects their response to drugs. It explains that people can metabolize and respond to drugs differently due to genetic variations. The goal of pharmacogenomics is to optimize drug therapy for each individual by selecting the right drug, dose, and time based on their genotype to maximize effectiveness and minimize side effects. It outlines how variations can influence whether receptors are present to bind drugs, other physiological traits, and how the body processes drugs through absorption, distribution, metabolism and excretion.
New treatment trends in alzheimer diseaseSarath Menon
This document summarizes new treatment trends in Alzheimer's disease. It discusses current treatments for mild-moderate Alzheimer's like donepezil, rivastigmine, and galantamine which are cholinesterase inhibitors. Memantine is used for more severe Alzheimer's as an NMDA receptor antagonist. Experimental therapies discussed include vaccines, secretase inhibitors, and stem cell therapy. Lifestyle factors like diet, exercise, and social support are also reviewed for prevention and management of Alzheimer's symptoms.
1. Dr. Barnes, there is currently no cure for AD and no disease-modifying
treatment, so the current best hope lies in identifying prevention strategies.
We believe our formulation will help
By 2050, as many as 16 million Americans will have
Alzheimer's and the cost of care will surpass $1
trillion annually."
2. The food and drug administration (FDA) has approved two drugs specifically to treat
symptoms of alzheimer's disease.
Cholinesterase inhibitors
Memantine
Sold under the brand namenda by forest laboratories inc and germany's merz pharma,
the drug had U.S.A Sales of about $1.2 billion last year.
For the study, researchers culled through published studies, presentations at medical
meetings and other sources to find studies that looked at the effectiveness of the drug
memantine, namenda's generic form, in patients with mild alzheimer's disease.
They found that memantine worked no better than a dummy pill at treating the
disease.
3. Under the microscope, there were widespread fatty deposits
in small blood vessels, dead and dying brain cells, and
abnormal protein amyloid deposits in and around cells.
AB1-40
4. Act on Extracellular neuritic amyloid plaques
Act on intracellular neurofibrillary tangles
Act as cholinesterase inhibitor
5. The value of the Alzheimer’s disease market across the
seven major markets was $4.7bn in 2009 and is forecast to
reach $11.9bn by 2019. Future market growth is set to be
driven by the first disease-modifying drugs, given their
significant price premium, likely therapeutic role as an
adjunctive and potential utility in prodromal Alzheimer's
diseaseDatamonitor forecasts that the current late-stage
pipeline will yield three blockbusters, but this is by no
means guaranteed considering the high risk of failure in
Phase III Alzheimer’s disease trials. Of the pipeline drugs,
Datamonitor believes that bapineuzumab and solanezumab
have the most commercial and clinical
potential.Datamonitor expects the symptomatic market will
remain active in this disease. New symptomatic entrants to
the market will include Aricept patch and the first-in-class
5-HT6 receptor antagonist SB-742457.
6. Worldwide, there are over 1000 published animal and human studies, both in vivo and in vitro in
which the effects of curcumin on various diseases have been examined. Studies include
epidemiological, basic and clinical research on AD.
7. We took advantage of existing knowledge of
curcumin and literature associated with its
limitations.
The biggest limitation is its solubility and
hence the absorption when consumed orally.
Stability is another issue
CUBX has curcumin properties in it
Our Hybrid Drug works Synergistically for two
pathological hallmark of AD i.e extracellular
neuritic amyloid plaques and intracellular
neurofibrillary tangles.
8. We resolved the issue of solubility and stability
of it
Our CUBXZIL molecule is soluble in water
Our CUBXZIL is not altered by any chemical
Our CUBXZIL is stable
9. Progressive Stages of Alzheimer’s Disease
Stage 1. ( Early or Mild):
Short term memory problems
May be unable to find the right words
Forgets familiar names and telephone numbers
Begins to write reminders but loses notes
Shows preference for familiar things
(Wears the same clothes, Avoids going out)
Judgment may be impaired
(May dress inappropriately for the weather)
We must try this drug to avoid progression
10. Progressive Stages of Alzheimer’s Disease
Stage 2a. (Middle or Moderate)):
Deterioration of ability to initiate and sequence
purposeful activities like bathing and driving
Sleep disturbance with restlessness at night
Begins to neglect health and hygiene
Needs directions to function in familiar
surroundings
We must try this drug to avoid progression
11. Progressive Stages of Alzheimer’s Disease
Stage 2b. (Middle or Moderate)
May lose ability to perform daily skills
(like buttoning a shirt or using a knife & fork)
May need to be told each step of a former routine act
(like brushing teeth or getting dressed)
May walk with a shuffling gait or may seem “glued to
the floor” due to a physical inability to walk
Often needs physical assistance with activities of
daily living (dressing, bathing, eating)
Needs protection and supervision
May lose the ability to read or write
12. Progressive Stages of Alzheimer’s Disease
Stage 3. (Late or Final):
Can’t walk
May discontinue talking or be unable to talk
Trouble swallowing
May have seizures
Incontinence
May make loud unintelligible negative noises or
sounds
Complete withdrawal or apathy
May lose control of outer extremities
Unable to survive without total care
WE MUST ACT BEFORE THIS
13. Alzheimer’s is the fifth leading cause of
disease death in the U.S.
Our molecule is really affordable to use. It
is safe and is reported to help.
Become part of the solution and bring
an end to this devastating disease!
I will be really be glad even if I would able to
contribute a little
14. Generic Brand Approved For and Side Effects
donepezil
Aricept
All stages
Nausea, vomiting, loss of appetite and increased frequency of bowel movements.
galantamine
Razadyne
Mild to moderate
Nausea, vomiting, loss of appetite and increased frequency of bowel movements.
memantine
Namenda
Moderate to severe
Headache, constipation, confusion and dizziness.
rivastigmine
Exelon
Mild to moderate
Nausea, vomiting, loss of appetite and increased frequency of bowel movements.
tacrine
Cognex
Mild to moderate
Possible liver damage, nausea, and vomiting.
vitamin E
Not applicable
Not approved
Can interact with medications prescribed to lower cholesterol or prevent blood clots; may slightly increase risk of death.
15. At this point we can not
disclose the full and
final information about
our nanomedicine
compound drug.
16. Since ours is showing great results for arthritis
and cancer.
Our is not formulated in any kind of protein
Our is more stable and more potent
It is safe and we are looking for clinical
collaboration.
Doctors, organizations or community help
17. To treat inflammation
To treat stress
To treat cholinesterase inhibitor
18.
19. Dr. Mewa Singh
mewasinghsandhu@hotmail.com
www.nanomeda.com
www.nanosgroup.com
LAETC, LSU Campus
Baton Rouge, LA